3-(4-Iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Catalog No.: 
ACWTHN172
CAS No.: 
2207541-30-6
Molecular Formula: 
C13H11IN2O3
Molecular Weight: 
370.15
3-(4-Iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$55.00In stockIn stock
1g95%$102.00In stockIn stock
5g95%$392.00In stockIn stock
25g95%$1941.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(4-Iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione
IUPAC Name3-(4-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione
MDL No.MFCD32862119
Molecular FormulaC13H11IN2O3
Molecular Weight370.15
SMILESN1C(=O)C(N2C(=O)C3=C(C(=CC=C3)I)C2)CCC1=O
InChI KeyBKIUJJLYXXEGFT-UHFFFAOYSA-N
Synonym2,6-Piperidinedione, 3-(1,3-dihydro-4-iodo-1-oxo-2H-isoindol-2-yl)-;3-(4-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione;Lenalidomide-I
CAS No.2207541-30-6
PubChem CID134348132

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACWTHN172 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACWTHN172 route product structure diagram
    ACWTHN1722207541-30-6In Stock
Inquiry

2. ACWTHN172 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACWTHN172 route product structure diagram
    ACWTHN1722207541-30-6In Stock
Inquiry

3. ACWTHN172 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACWTHN172 route product structure diagram
    ACWTHN1722207541-30-6In Stock
Inquiry

Comments (0)